- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Replimune Group Inc (REPL)Replimune Group Inc stock price live, this page displays NASDAQ REPL stock exchange data. View the REPL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Replimune Group Inc real time stock price chart below.
What Is the Replimune Group Inc Stock Price Today?
The Replimune Group Inc stock price today is 12.69.
What Is the Stock Symbol for Replimune Group Inc?
The stock ticker symbol for Replimune Group Inc is REPL.
Is REPL the Same as $REPL?
$REPL is a common way to refer to the Replimune Group Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Replimune Group Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REPL quote. (ISIN: US76029N1063)
What Is the Replimune Group Inc Stock Price Today?
The Replimune Group Inc stock price today is 12.69.
What Is the Stock Symbol for Replimune Group Inc?
The stock ticker symbol for Replimune Group Inc is REPL.
Is REPL the Same as $REPL?
$REPL is a common way to refer to the Replimune Group Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Replimune Group Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REPL quote. (ISIN: US76029N1063)
12.69
+0.05(+0.40%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.29
12.79
52 wk Range
4.92
17.00
REPL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.2912.79
52 wk Range
4.9217.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
REPL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
16.88
Upside
+33.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Replimune Group Inc Company Profile
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group Inc SWOT Analysis
Strategic Positioning | Delve into Replimune's growth strategies, including pipeline expansion beyond RP1 and in-house manufacturing capabilities, amidst a competitive oncology landscape |
Financial Outlook | Learn about Replimune's solid cash position, supporting operations into 2026, and analyst projections of $481 million peak sales for RP1 by 2033 |
Clinical Promise | Explore RP1's encouraging efficacy data in advanced melanoma, including durable responses and improved survival rates in difficult-to-treat patients |
Milestone Approach | Replimune nears BLA submission for RP1 in advanced melanoma, with potential accelerated approval pathway and key clinical trial progress |
Compare REPL to Peers and Sector
Metrics to compare | REPL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREPLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.5x | −4.2x | −0.6x | |
PEG Ratio | 1.28 | −0.10 | 0.00 | |
Price / Book | 2.5x | 1.8x | 2.6x | |
Price / LTM Sales | - | 33.3x | 3.2x | |
Upside (Analyst Target) | 34.5% | 138.9% | 40.6% | |
Fair Value Upside | Unlock | 15.2% | 7.1% | Unlock |
Analysts' Recommendations
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 16.88
(+32.98% Upside)
People Also Watch
FAQ
What Is the Replimune (REPL) Stock Price Today?
The Replimune stock price today is 12.69
What Stock Exchange Does Replimune Trade On?
Replimune is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Replimune?
The stock symbol for Replimune is "REPL."
What Is the Replimune Market Cap?
As of today, Replimune market cap is 956.07M.
What is Replimune Earnings Per Share?
The Replimune EPS is -3.20.
What Is the Next Replimune Earnings Date?
Replimune will release its next earnings report on Feb 06, 2025.
From a Technical Analysis Perspective, Is REPL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.